Adaptive and Innate Misfires: Distinguishing Autoimmune and Autoinflammatory Disorders

Dhanvin Chiragbhai Suthar*[1]
Doctor of Pharmacy (Pharm.D.), SAL Institute of Pharmacy, Ahmedabad, Gujarat, India[1]*

Abstract- ***Autoimmune and autoinflammatory disorders are two different categories of immune-mediated diseases characterised by dysregulation of adaptive and innate immunity, respectively. Despite the differences in their pathogenesis, these conditions are frequently used interchangeably, leading to challenges in diagnosis and management. This review aims to provide clarity regarding the distinction, overlap, diagnostic approaches, and treatment strategies associated with both disease groups. A literature search was conducted using Google Scholar to identify relevant peer-reviewed medical review and research articles. The review compares autoimmune and autoinflammatory disorders on the basis of disease characteristics, pathogenesis, differential diagnosis, and therapeutic interventions. Additionally, overlap disorders such as Behçet disease, psoriatic arthritis, and Adult-onset Still's disease are discussed to highlight the interaction between innate and adaptive immune mechanisms. Understanding these differences is essential for accurate diagnosis, targeted therapy selection, and improved patient outcomes in clinical practice.***

Keywords- ***immune-mediated disorders, autoimmune diseases, autoinflammatory diseases, dysregulated innate immunity, dysregulated adaptive immunity***

I. INTRODUCTION

The immune system plays a vital role in defending the body against infections. However, when immune responses become dysregulated, they can cause immune-mediated diseases. In such cases, the immune system acts as a double-edged sword, capable of both protection and injury. Historically, many inflammatory diseases were classified as autoimmune. However, recent advances in immunological research have identified a distinct category of disorders termed autoinflammatory diseases. Although both groups fall under immune-mediated conditions, their pathophysiology differs significantly, necessitating separate classification [1].

Immune-mediated diseases are broadly divided into two categories: (i) autoimmune disorders and (ii) autoinflammatory disorders. This distinction is based on differences in pathophysiology, diagnostic approaches, and therapeutic interventions. Autoimmune diseases are primarily driven by maladaptive responses of the adaptive immune system, involving autoreactive T cells and autoantibodies. In contrast, autoinflammatory diseases arise from dysregulation of the innate immune system, often linked to activation of inflammatory cascades through excessive cytokine release [1].

II. REVIEW OF LITERATURE

A. Autoimmune Diseases

Autoimmune diseases are disorders caused by dysregulated adaptive immunity. These conditions are characterized by a loss of self-tolerance within the immune system. Autoantibodies and/or autoreactive T lymphocytes generate a dysregulated immune response, with varying involvement across the spectrum of disorders, ultimately leading to immune-mediated damage to host tissues. Examples of autoimmune diseases include Systemic Lupus Erythematous (SLE), Rheumatoid Arthritis (RA), Type I Diabetes Mellitus, Multiple Sclerosis etc [2].

Pathogenesis: Autoimmune diseases follow a pathogenesis that involves a complex interaction of genetic and environmental factors. Individuals with genetic susceptibility carry certain alleles that predispose their immune system to dysfunction. When these susceptible individuals are exposed to environmental triggers (e.g., infections, drugs, etc.) or other external stimuli, disease onset or manifestation may occur with associated symptoms. This process reduces the threshold of immune response the host body can tolerate without adverse effects, a phenomenon known as loss of immune tolerance. As a result, the immune system fails to distinguish between self and non-self. This loss of immune tolerance leads to the activation of autoreactive T and B lymphocytes, which initiate an immune response against the body's own tissues. Activation of these cells induces production of

autoantibodies and the release of pro-inflammatory cytokines, further intensifying immune activity. Altogether, these phenomena culminate in tissue inflammation, facilitating tissue damage and disease progression marked by the appearance of its clinical manifestations [1].

B. Autoinflammatory Diseases

Autoinflammatory diseases are a group of disorders caused by dysregulation of the innate immune system. These conditions are characterised by recurrent episodes of systemic inflammation. Unlike autoimmune disorders, autoinflammatory diseases are not associated with the presence of autoantibodies or antigen-specific T lymphocytes. They are frequently linked to genetic mutations affecting innate immune signalling pathways. Examples of autoinflammatory diseases include Familial Mediterranean Fever (FMF), Cryopyrin-Associated Periodic Syndromes (CAPS), and TNF Receptor-Associated Periodic Syndrome (TRAPS) [3].

Pathogenesis: Autoinflammatory diseases involve dysregulation of the innate immune system triggered by genetic mutations affecting immune regulatory pathways. These mutations alter the function of innate immune sensors or cytokine regulatory proteins, leading to abnormal activation of inflammatory pathways. As a result, the altered immune sensors fail to regulate inflammatory responses effectively, causing exaggerated activation of immune signalling mechanisms. A major consequence of this dysregulation is excessive production of pro-inflammatory cytokines, particularly interleukin-1 (IL-1), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α). Increased cytokine release further amplifies inflammatory cascades and promotes activation of immune cells such as neutrophils and macrophages. Unlike autoimmune diseases, this inflammatory process occurs independently of autoantibodies or antigen-specific T-cell responses. Uncontrolled cytokine-mediated inflammation leads to recurrent episodes of systemic inflammation affecting multiple organs and tissues. Repeated inflammatory attacks contribute to tissue injury and chronic inflammatory complications over time. Clinical manifestations are recurrent and commonly include fever, skin rashes, serositis, arthralgia, and other inflammatory symptoms depending on the specific disease subtype [4].

C. Differential Diagnosis of Autoimmune and Autoinflammatory Diseases

Differential diagnosis between autoimmune and autoinflammatory disorders involves careful evaluation of clinical presentation, laboratory findings, genetic predisposition, and immune mechanisms. Autoimmune diseases are characterised by adaptive immune dysregulation, often demonstrating the presence of autoantibodies, autoreactive T cells, and antigen-specific immune responses. Laboratory investigations commonly reveal positive serological markers such as antinuclear antibodies or rheumatoid factor. On the other hand, autoinflammatory disorders result mainly from dysregulation of the innate immune system and are typically associated with recurrent episodes of systemic inflammation, elevated inflammatory markers, and absence of significant autoantibodies or autoreactive lymphocytes. Clinical manifestations, including episodic fever patterns, organ involvement, and response to targeted therapies such as IL-1 inhibitors, further assist in distinguishing between the two conditions. Certain disorders showcase overlapping immunopathogenic features; thus, an integrated diagnostic approach combining clinical assessment, immunological investigations, and molecular studies is essential for accurate classification and appropriate management [5,6].

D. Selecting Appropriate Management Approaches for Immune-Mediated Disorders

1) *Importance of Selecting Appropriate Treatment Approaches:* Selecting appropriate treatment strategies for autoimmune and autoinflammatory diseases is essential because both conditions involve distinct immunopathogenic mechanisms. Autoimmune diseases primarily result from dysregulation of the adaptive immune system, whereas autoinflammatory disorders are mainly associated with abnormalities of innate immune responses. Therefore, therapeutic interventions must target different inflammatory pathways and immune mediators. Inappropriate treatment selection may lead to ineffective disease management, persistent inflammation, unnecessary immunosuppression, or increased risk of complications.
2) *Treatment Approaches for Autoimmune Disorders:* Management of autoimmune disorders primarily focuses on suppressing

abnormal adaptive immune responses and preventing progressive tissue damage. Treatment strategies are selected on the basis of the severity of the disease, organ involved, and clinical manifestations. Pharmacological therapy includes corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, azathioprine, or mycophenolate mofetil. In severe or refractory cases, biologic agents targeting specific immune pathways are used. These include tumour necrosis factor inhibitors (TNF-inhibitors), B-cell-targeted therapies, and monoclonal antibodies targeting cytokines or immune receptors. Long-term management also involves regular monitoring of disease activity, prevention of treatment-related adverse effects, and supportive care measures. Since autoimmune diseases are chronic and relapsing, therapeutic decisions must aim to achieve sustained remission while minimising systemic toxicity and preserving organ function. Individualised treatment plans based on immunological profile, clinical response, and patient-specific factors are therefore essential for effective disease control and improved prognosis [2].

3) *Treatment Approaches for Autoinflammatory Disorders:* Treatment approaches for autoinflammatory disorders mainly target dysregulated innate immune pathways and excessive cytokine-mediated inflammation. Management strategies are based on the severity of systemic inflammation, frequency of disease flares, and extent of organ involvement. Conventional anti-inflammatory agents such as non-steroidal anti-inflammatory drugs and corticosteroids may provide symptomatic relief during acute inflammatory episodes. Targeted biologic therapies can significantly improve disease outcomes in many autoinflammatory conditions. Interleukin-1 inhibitors, including anakinra and canakinumab, are highly effective in disorders associated with excessive IL-1 activity. Additionally, biologic agents targeting IL-6 or tumour necrosis factor may also be used in selected conditions. Monitoring of inflammatory markers, and prevention of long-term complications such as amyloidosis are essential for optimal patient outcomes. Since autoinflammatory disorders frequently involve recurrent systemic inflammation and variable clinical manifestations, treatment selection should be individualised and directed towards controlling inflammatory pathways along with simultaneously improving overall quality of life and functional outcomes [5].

E. Overlap in Immune-Mediated Diseases

Certain immune-mediated diseases comprise the characteristics of both autoimmune diseases and autoinflammatory diseases, highlighting the interaction between adaptive and innate immune pathways. These disorders cannot be classified strictly into a single category because they involve overlapping mechanisms such as cytokine dysregulation, chronic inflammation, autoreactive immune responses, and genetic susceptibility [6]. Some examples of immune-mediated diseases that possess features of both autoimmune and autoinflammatory disorders are discussed in this review.

1) *Behçet Disease:* Behçet disease demonstrates overlap through exaggerated innate immune activation alongside adaptive immune abnormalities. Neutrophil hyperactivity, elevated inflammatory cytokines, and recurrent mucocutaneous inflammation suggest autoinflammatory mechanisms, while T-cell dysregulation and associations with HLA-B51 indicate autoimmune involvement [7].
2) *Psoriatic Arthritis:* Psoriatic arthritis exhibits both innate and adaptive immune dysregulation. Cytokines such as TNF-α, IL-17, and IL-23 contribute to inflammatory pathways characteristic of autoinflammatory conditions, while autoreactive T-cell responses and chronic synovial inflammation resemble autoimmune pathology. The disease therefore represents an intermediate immune-mediated disorder with mixed immunopathogenic mechanisms [8].
3) *Adult-onset Still's Disease:* Adult-onset Still's disease is considered

predominantly autoinflammatory due to excessive innate immune activation and marked IL-1 and IL-6 cytokine production. However, chronic arthritis and persistent systemic inflammation may involve adaptive immune responses [9].

III. METHODOLOGY

The methodology for this review involved systematic topic selection, literature evaluation, comparative analysis, and structured drafting of the manuscript sections. The topic was selected to address the increasing confusion surrounding autoimmune and autoinflammatory disorders, which are frequently used interchangeably despite having distinct immunopathogenic mechanisms. The primary objective of the review was to provide clarity to healthcare professionals as well as individuals from non-healthcare backgrounds regarding the differences, overlap, and clinical significance of these two groups of immune-mediated diseases. A literature search was conducted using Google Scholar to identify relevant medical review articles and research publications. The inclusion criteria comprised peer-reviewed medical review and research articles focusing on the distinction, overlap, immunological characteristics, pathogenesis, differential diagnosis, and treatment approaches of autoimmune and autoinflammatory disorders. Articles discussing diseases demonstrating overlap between innate and adaptive immune dysregulation were also included. The exclusion criteria involved academically insufficient articles that were not based on clinical research, did not constitute a review of medical literature, lacked proper reference citations, or failed to specify reliable sources of information. Following literature selection, both disease groups were compared on the basis of definition, pathogenesis, differential diagnosis, and treatment approaches. Individual disease examples representing overlap between the two immune mechanisms were identified and incorporated into the review according to their relevance to the topic. The introduction and review of literature sections were then drafted. Subsequently, the ‘discussions’ section was developed through critical evaluation and synthesis of findings obtained from the selected literature. Finally, a conclusion was drafted to emphasise the major differences between the two disease groups and highlight the importance of accurate distinction for improving diagnostic precision, treatment selection, and overall patient outcomes. Reference formatting was performed using Vancouver style with the aid of Mendeley reference management software, while in-text citations were inserted manually throughout the review.

IV. DISCUSSIONS

Distinguishing between autoimmune and autoinflammatory disorders is becoming increasingly important with advances in immunology and molecular medicine. Although both groups of diseases fall under the category of immune-mediated disorders, they differ significantly in terms of immunopathogenesis, clinical manifestations, diagnostic markers, and therapeutic approaches. Autoimmune diseases primarily involve dysregulation of adaptive immunity, characterised by autoreactive T lymphocytes, B lymphocytes, and the production of autoantibodies. Whereas autoinflammatory disorders mainly arise from abnormalities of innate immune mechanisms involving excessive cytokine-mediated inflammation and dysregulated activation of immune cells such as neutrophils and macrophages. This distinction is clinically significant because inappropriate classification may delay diagnosis and lead to ineffective therapeutic interventions.

The reviewed literature showed that autoimmune diseases typically follow a chronic and progressive course associated with persistent immune activation and tissue damage. Loss of self-tolerance represents a major pathogenic mechanism, with environmental triggers acting upon genetically susceptible individuals. Autoinflammatory diseases are commonly characterised by recurrent inflammatory episodes without significant involvement of autoantibodies or antigen-specific T-cell responses. Genetic mutations affecting inflammatory signalling pathways contribute substantially to the development of many autoinflammatory disorders. These differences explain the variation in clinical presentation, laboratory findings, and disease progression between the two groups.

Another important finding is the existence of overlap disorders demonstrating features of both autoimmune and autoinflammatory mechanisms. Diseases such as Behçet disease, psoriatic arthritis, Adult-onset Still’s

disease, and Crohn's disease illustrate the complex interaction between innate and adaptive immune responses. These disorders challenge the binary classification of immune-mediated diseases and instead support the concept of an immunological spectrum. Cytokine dysregulation, chronic inflammation, and genetic susceptibility contribute to this overlap, indicating that immune-mediated disorders may not always fit into specific diagnostic categories. Thus, recognition of these overlap conditions is essential for accurate diagnosis and selection of targeted therapies.

The literature review also highlighted the importance of differential diagnosis in clinical practice. Autoimmune diseases demonstrate positive serological markers such as antinuclear antibodies or rheumatoid factor, whereas autoinflammatory disorders are generally associated with elevated inflammatory markers and recurrent febrile episodes in the absence of significant autoantibodies. Integrated diagnostic approaches combining clinical evaluation, laboratory investigations, and molecular studies therefore play a crucial role in distinguishing between these conditions.

Therapeutically, accurate classification directly influences management outcomes. Autoimmune diseases often require immunosuppressive agents and biologic therapies targeting adaptive immune pathways, whereas autoinflammatory disorders respond more effectively to cytokine-targeted therapies such as IL-1 inhibitors. This demonstrates the importance of precise diagnosis for selecting appropriate treatment strategies, reducing disease-related complications, and improving long-term patient outcomes. Overall, the reviewed literature supports the need for greater awareness regarding the distinctions and overlap between autoimmune and autoinflammatory disorders in both clinical and academic settings.

V. CONCLUSION

Autoimmune and autoinflammatory disorders represent distinct yet interconnected groups of immune-mediated diseases characterised by dysregulation of adaptive and innate immunity, respectively. Although both conditions share inflammatory manifestations, they differ significantly in pathogenesis, diagnostic markers, and therapeutic approaches. The presence of overlap disorders further highlights the complexity of immune system dysregulation and the importance of understanding the immunological spectrum rather than relying on binary disease classification. Accurate differentiation between these conditions is essential for timely diagnosis, appropriate treatment selection, and prevention of disease-related complications. Improved awareness among healthcare professionals may contribute to enhanced patient management, personalised therapy, and better long-term clinical outcomes.

REFERENCES

[1] N. R. Rose and C. Bona, "Defining criteria for autoimmune diseases (Witebsky's postulates revisited)," Immunol Today, vol. 14, no. 9, pp. 426–430, Sep. 1993, doi: 10.1016/0167-5699(93)90244-F.

[2] A. Davidson and B. Diamond, "Autoimmune Diseases," New England Journal of Medicine, vol. 345, no. 5, pp. 340–350, Aug. 2001, doi: 10.1056/NEJM200108023450506.

[3] D. L. Kastner, I. Aksentijevich, and R. Goldbach-Mansky, "Autoinflammatory Disease Reloaded: A Clinical Perspective," Cell, vol. 140, no. 6, pp. 784–790, Mar. 2010, doi: 10.1016/j.cell.2010.03.002.

[4] S. L. Masters, A. Simon, I. Aksentijevich, and D. L. Kastner, "Horror Autoinflammaticus : The Molecular Pathophysiology of Autoinflammatory Disease," Annu Rev Immunol, vol. 27, no. 1, pp. 621–668, Apr. 2009, doi: 10.1146/annurev.immunol.25.022106.141627.

[5] K. Abacar, T. Macleod, H. Direskeneli, and D. McGonagle, "How underappreciated autoinflammatory (innate immunity) mechanisms dominate disparate autoimmune disorders," Front Immunol, vol. 15, Sep. 2024, doi: 10.3389/fimmu.2024.1439371.

[6] D. McGonagle and M. F. McDermott, "A Proposed Classification of the Immunological Diseases," PLoS Med, vol. 3, no. 8, p. e297, Aug. 2006, doi: 10.1371/journal.pmed.0030297.

[7] A. Gül, "Pathogenesis of Behçet's disease: autoinflammatory features and beyond," Semin Immunopathol, vol. 37, no. 4, pp. 413–418, Jul. 2015, doi: 10.1007/s00281-015-0502-8.

[8] A. B. Azuaga, J. Ramírez, and J. D. Cañete, "Psoriatic Arthritis: Pathogenesis and Targeted Therapies," Int J Mol Sci, vol. 24, no. 5, p. 4901, Mar. 2023, doi: 10.3390/ijms24054901.

[9] S. Rao, L. S.-L. Tsang, M. Zhao, W. Shi, and Q. Lu, "Adult-onset Still's disease: A disease at the crossroad of innate immunity and autoimmunity," Front Med (Lausanne), vol. 9, Aug. 2022, doi: 10.3389/fmed.2022.881431.